Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.